drugset / Trial / NCT00356928
Cyclophosphamide Plus T-Cell Transplantation for Patients With Hematologic Malignancies
Phase 1
Terminated
14 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of abnormal blood cells, either by killing the cells or by stopping them from dividing. Giving cyclophosphamide together with donor lymphocytes that have been treated in the laboratory may be an effective treatment for myelodysplastic syndromes or myeloproliferative disorders. PURPOSE: This clinical trial is studying the best dose of donor lymphocytes when given together with cyclophosphamide in treating patients with myelodysplastic syndromes or myeloproliferative disorders.
Timeline
- Start
- 2006-10
- Primary completion
- 2011-05
- Completion
- 2011-05
Outcome
Outcome not reported
Stopped (Enrollment): “Poor accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Donor T cells | Cell therapy | 100000 cells/kg | Intravenous |
| Subject | Donor T cells | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | Donor T cells | Cell therapy | 1e+07 cells/kg | Intravenous |
| Subject | Donor T cells | Cell therapy | 5e+07 cells/kg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 50 mg/kg | Intravenous |